

WHO DRUG INFORMATION

Contents

General Policy Topics

- Bioavailability and bioequivalence: moves towards consensus 1

Personal Perspectives

- Counterfeits: grappling with the issues 3

Reports on Individual Drugs

- Artemether in children with severe malaria 6
IUDs and pelvic inflammatory disease: a reassuring assessment 6
Leprosy: interim appraisal of an *M. leprae* vaccine 7
Quinine: use of loading doses in falciparum malaria 8
More new experience with oral and parenteral typhoid vaccines 9
Vitamin A supplements and childhood mortality: further encouraging evidence 11

General Information

- Tuberculosis chemotherapy: the case for defining national policies 12
Vaccine selection: safety versus immunogenicity 13
Advertising standards reviewed 14

Regulatory Matters

- ACE inhibitors and anaphylaxis in patients undergoing haemodialysis 15
Chlorofluorocarbons: restrictions in use 15
Corticosteroids: danger of immunosuppression 15
Didanosine: approved for advanced HIV infection 15
Foscarnet sodium for cytomegalovirus retinitis in advanced HIV infection 16
Metamizole sodium: restrictive rescheduling 16
Noscapine: removed from opium alkaloid preparations 16

Advisory Notices

- Beta adrenoreceptor agonists and asthma 17
1% hydrocortisone products available without prescription 17
Nandrolone: do risks outweigh benefits? 18

Essential Drugs

- Sexually transmitted diseases 19
Aciclovir 29
Benzylpenicillin 30
Benzathine benzylpenicillin 30
Procaine benzylpenicillin 30
Ceftriaxone 31
Ciprofloxacin 31
Erythromycin 32
Metronidazole 33
Miconazole 33
Nystatin 34
Podophyllum resin 34
Spectinomycin 35
Sulfamethoxazole/trimethoprim 35
Tetracycline 36
Doxycycline 37

Recent Publications

- Biological standards: international standards and reference reagents 38
WHO Expert Committee on Biological Standardization 38

Recommended International Nonproprietary Names: List 31

- Amendments (*Continued*) 39

WHO DRUG INFORMATION

WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters.

The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to provide an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken.

WHO Drug Information is published 4 times a year in English, French and Spanish and can be ordered from: Distribution and Sales Department, World Health Organization, 1211 Geneva 27, Switzerland.

Annual subscription: Sw. fr. 60.—

Airmail rate: Sw.fr. 72.—

Price per copy: Sw.fr. 20.—

© World Health Organization 1992

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation, in part or *in toto*, application should be made to: Chief, Office of Publications, World Health Organization, 1211 Geneva 27, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Authors alone are responsible for views expressed in signed contributions.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

ISSN 1010-9609